Invex Therapeutics Ltd (IXC.AX)

0.0760 -0.0020 (-2.56%) At close: 01:39PM AEST

Invex Therapeutics Ltd

38 Rowland Street
Level 2 Subiaco
Perth, WA 6008
Australia
61 8 6382 0137
https://www.invextherapeutics.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Narelle Warren B.Com., L.L.B., B.Com, LLB	CFO & Company Secretary	135k	N/A	N/A
Dr. Thomas Duthy M.B.A., Ph.D.	Executive Director	180k	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in AUD.

Description

Invex Therapeutics Ltd, a biopharmaceutical company, engages in the research and development of treatments for neurological conditions in Australia. The company is involved in developing Exenatide, a treatment for neurological conditions derived from or involving raised intracranial pressure, such as idiopathic intracranial hypertension, acute stroke, and traumatic brain injury that has completed Phase II clinical trial. Invex Therapeutics Ltd was incorporated in 2019 and is based in Perth, Australia.

Corporate governance

Invex Therapeutics Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.